Your browser doesn't support javascript.
loading
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Lachowiez, Curtis A; Loghavi, Sanam; Zeng, Zhihong; Tanaka, Tomoyuki; Kim, Yi June; Uryu, Hidetaka; Turkalj, Sven; Jakobsen, Niels Asger; Luskin, Marlise R; Duose, Dzifa Y; Tidwell, Rebecca S S; Short, Nicholas J; Borthakur, Gautam; Kadia, Tapan M; Masarova, Lucia; Tippett, George D; Bose, Prithviraj; Jabbour, Elias J; Ravandi, Farhad; Daver, Naval G; Garcia-Manero, Guillermo; Kantarjian, Hagop; Garcia, Jacqueline S; Vyas, Paresh; Takahashi, Koichi; Konopleva, Marina; DiNardo, Courtney D.
Affiliation
  • Lachowiez CA; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Loghavi S; The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas.
  • Zeng Z; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Tanaka T; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Kim YJ; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Uryu H; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Turkalj S; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Jakobsen NA; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Luskin MR; Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
  • Duose DY; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Tidwell RSS; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Short NJ; Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
  • Borthakur G; Dana-Farber Cancer Institute, Leukemia Program, Boston, Massachusetts.
  • Kadia TM; The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, Houston, Texas.
  • Masarova L; The University of Texas MD Anderson Cancer Center, Department of Biostatistics, Houston, Texas.
  • Tippett GD; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Bose P; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Jabbour EJ; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Ravandi F; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Daver NG; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Garcia-Manero G; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Kantarjian H; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Garcia JS; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Vyas P; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Takahashi K; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • Konopleva M; The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas.
  • DiNardo CD; Dana-Farber Cancer Institute, Leukemia Program, Boston, Massachusetts.
Blood Cancer Discov ; 4(4): 276-293, 2023 07 05.
Article in En | MEDLINE | ID: mdl-37102976
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasm Recurrence, Local / Antineoplastic Agents Limits: Humans Language: En Journal: Blood Cancer Discov Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasm Recurrence, Local / Antineoplastic Agents Limits: Humans Language: En Journal: Blood Cancer Discov Year: 2023 Document type: Article